KD 026

Drug Profile

KD 026

Alternative Names: KD026; SLX 4090; SLx-4090

Latest Information Update: 25 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Surface Logix
  • Developer Kadmon Pharmaceuticals
  • Class Antihyperglycaemics; Antihyperlipidaemics; Benzamides; Isoquinolines; Obesity therapies; Small molecules
  • Mechanism of Action Microsomal triglyceride transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • No development reported Dyslipidaemias; Obesity

Most Recent Events

  • 01 Mar 2016 Kadmon Pharmaceuticals completes a phase II trial for Type 2 diabetes mellitus (Combination therapy) in USA (NCT02434744)
  • 20 Aug 2015 No recent reports on development identified - Phase-II for Dyslipidaemias in USA and Germany (PO)
  • 20 Aug 2015 No recent reports on development identified - Phase-II for Obesity in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top